|
FDA Pushes Back Review of Two Novo Nordisk Diabetes Candidates
Novo Nordisk will have to wait until late October to get word on the fate of two ultra-long-acting insulin treatments because the FDA needs additional time to review data clarifications and analyses it requested after the initial NDA submissions.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives